Results 151 to 160 of about 802 (167)

Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study

Expert Opinion on Drug Safety, 2020
Kohei Kaku, Yusuke Naito, Atsutaka Yasui   +2 more
exaly  

The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance

Japanese Journal of Clinical Oncology, 2023
Hirotsugu Uemura, Nobuo Shinohara, Yoshihiko Tomita   +2 more
exaly  

Post-marketing safety surveillance of erenumab: new insight from Eudravigilance

Expert Opinion on Drug Safety, 2022
David Liang, Maurizio Sessa
exaly  

Intussusception following rotavirus vaccine administration: Post-marketing surveillance in the National Immunization Program in Australia

Vaccine, 2011
John B Carlin, Elizabeth J Elliott, Robert Booy   +2 more
exaly  

Clinical trials in post-marketing surveillance of drugs

Contemporary Clinical Trials, 1982
E O'Brian Smith
exaly  

Safety of the Xuesaitong injection in China: results from a large-scale multicentre post-marketing surveillance study in a real-world setting

Current Medical Research and Opinion, 2020
Xue-Min Gao
exaly  

Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan

Modern Rheumatology, 2017
Tsuneyo Mimori, Takao Fujii, Shigeki Momohara   +2 more
exaly  

Safety and effectiveness of istradefylline in patients with Parkinson’s disease: interim analysis of a post-marketing surveillance study in Japan

Expert Opinion on Pharmacotherapy, 2018
Makio Takahashi, Akihisa Mori
exaly  

Fatal adverse drug reactions of anticancer drugs detected by all-case post-marketing surveillance in Japan

Japanese Journal of Clinical Oncology, 2015
Jinichi Mori, Tetsuya Tanimoto, Yuji Miura   +2 more
exaly  

Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): Post-marketing surveillance in Japan

Modern Rheumatology, 2018
Tsutomu Takeuchi, Takeuchi Tsutomu
exaly